Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men—a randomized, placebo-controlled study

Objectives:To determine the effect of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, pravastatin, on markers of cardiovascular risk and lipodystrophy in HIV-infected, protease inhibitor (PI)-treated men with hypercholesterolaemia. Methods:A randomized, placebo-controlled, 16-week study was carried out on 33 HIV-infected, hypercholesterolaemic men (fasting total cholesterol > 6.5mmol/L) on PI-containing therapy. Patients commenced dietary assessment and advice at week 0 and were randomized to 12 weeks pravastatin (40 mg each night) or placebo from week 4. The primary endpoint was the time-weighted change (TWAUC) in total cholesterol from week 0. Secondary endpoints included TWAUC cholesterol from week 4 (start of pravastatin), total and regional body fat, fasting lipids, glucose, insulin, and markers of cardiovascular risk. Results:Of 33 men randomized (pravastatin n = 16, mean age 48 years), 31 completed the study. Groups were matched for baseline cholesterol and body composition. Although there was no significant between-group difference in TWAUC cholesterol from week 0 (pravastatin −0.6 ± 1.0 versus placebo −0.4 ± 1.0 mmol/L/week; P = 0.8), TWAUC cholesterol from week 4 decreased more in the pravastatin group (−0.8 ± 1.0 versus −0.3 ± 0.9 mmol/L/week; P = 0.04). Neither triglycerides nor dietary intake changed. Subcutaneous fat increased significantly with pravastatin (+0.72 ± 1.55 versus +0.19 ± 0.48 kg change in limb fat, P < 0.04; +5.2 ± 8.7 versus −1.3 ± 13.7 cm2 change in abdominal subcutaneous fat, P = 0.02). Apart from homocystine, which decreased in the pravastatin group, there were no significant differences in other cardiovascular, lipid or glucose parameters. Conclusions:Despite limited effects on cholesterol, 12 weeks use of pravastatin 40 mg each night in HIV-infected men with hypercholesterolaemia resulted in significant increases in subcutaneous fat.

[1]  Leonardo Calza,et al.  Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia , 2005, AIDS.

[2]  C. Fichtenbaum,et al.  Effect of Efavirenz on the Pharmacokinetics of Simvastatin, Atorvastatin, and Pravastatin: Results of AIDS Clinical Trials Group 5108 Study , 2005, Journal of acquired immune deficiency syndromes.

[3]  D. Cooper,et al.  In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. , 2005, The Journal of infectious diseases.

[4]  M. Gill,et al.  Changing mortality rates and causes of death for HIV‐infected individuals living in Southern Alberta, Canada from 1984 to 2003 , 2005, HIV medicine.

[5]  D. Cooper,et al.  Influence of Rosiglitazone on Flow-Mediated Dilation and Other Markers of Cardiovascular Risk in HIV-Infected Patients with Lipoatrophy , 2005, Antiviral therapy.

[6]  H. Klinker,et al.  Lipid Lowering Therapy with Fluvastatin and Pravastatin in Patients with HIV Infection and Antiretroviral Therapy: Comparison of Efficacy and Interaction with Indinavir , 2004, Infection.

[7]  T. Funahashi,et al.  Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy. , 2004, American journal of physiology. Endocrinology and metabolism.

[8]  D. Cooper,et al.  Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study , 2004, AIDS.

[9]  J. Stein,et al.  Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. , 2004, American heart journal.

[10]  D. Cooper,et al.  No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial , 2004, The Lancet.

[11]  Rodolphe Thiébaut,et al.  Combination antiretroviral therapy and the risk of myocardial infarction , 2003 .

[12]  D. D. de Luis,et al.  Pravastatin in hyperlipidemia secondary to HIV protease inhibitors without response to fenofibrate: a brief preliminary report. , 2003, Nutrition.

[13]  H. Milionis,et al.  Comparative Effects of Atorvastatin, Simvastatin, and Fenofibrate on Serum Homocysteine Levels in Patients with Primary Hyperlipidemia , 2003, Journal of clinical pharmacology.

[14]  S. Cole,et al.  Impact of HIV infection and HAART on serum lipids in men. , 2003, JAMA.

[15]  David A. Cooper,et al.  Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy , 2003, AIDS.

[16]  Leonardo Calza,et al.  Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART , 2003, AIDS.

[17]  D. Freedman,et al.  Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. , 2002, The American journal of cardiology.

[18]  D. Cooper,et al.  Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. , 2002, JAMA.

[19]  C. Fichtenbaum,et al.  Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047 , 2002, AIDS.

[20]  J. Layne,et al.  Reduction of abdominal obesity in lipodystrophy associated with human immunodeficiency virus infection by means of diet and exercise: case report and proof of principle. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  H. Jamil,et al.  HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia , 2001, Nature Medicine.

[22]  B. Gazzard,et al.  Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy , 2001, AIDS.

[23]  P. Rhodes,et al.  Clinical assessment of HIV-associated lipodystrophy in an ambulatory population , 2001, AIDS.

[24]  P. McBride,et al.  Use of Human Immunodeficiency Virus-1 Protease Inhibitors Is Associated With Atherogenic Lipoprotein Changes and Endothelial Dysfunction , 2001, Circulation.

[25]  L. Meyer,et al.  Lipodystrophy in 685 HIV-1–Treated Patients: Influence of Antiretroviral Treatment and Immunovirological Response , 2001, HIV clinical trials.

[26]  P. Ferré,et al.  Cholesterol, a Cell Size-dependent Signal That Regulates Glucose Metabolism and Gene Expression in Adipocytes* 210 , 2001, The Journal of Biological Chemistry.

[27]  A Ammassari,et al.  Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study. , 2000, AIDS.

[28]  D. Cooper,et al.  A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome , 2000, AIDS.

[29]  J. Leonard,et al.  Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects , 2000, AIDS.

[30]  J. Murillas,et al.  Atorvastatin for protease inhibitor-related hyperlipidaemia. , 1999, AIDS.

[31]  U. Christians,et al.  Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[32]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[33]  David A. Cooper,et al.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors , 1998, AIDS.

[34]  S. Ellis,et al.  Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. , 1995, Journal of the American College of Cardiology.

[35]  J. K. Lloyd,et al.  Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis , 1992, The Lancet.

[36]  A. Goldberg,et al.  Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once-daily versus twice-daily dosing. , 1990, Atherosclerosis.

[37]  A. Dobs,et al.  Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study. , 1990, Atherosclerosis.

[38]  G. Block,et al.  Human dietary assessment: methods and issues. , 1989, Preventive medicine.

[39]  H. Minuk,et al.  Metabolic syndrome. , 2005, Journal of insurance medicine.

[40]  D. Fuchs,et al.  Atorvastatin suppresses homocysteine formation in stimulated human peripheral blood mononuclear cells , 2005, Clinical chemistry and laboratory medicine.

[41]  P. Sax,et al.  Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. , 2004, Annals of internal medicine.

[42]  N. Boyd,et al.  A review of the methods used by studies of dietary measurement. , 1989, Journal of clinical epidemiology.

[43]  E. Loken,et al.  Methods for data collection at an individual level. , 1988 .